1,454 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Symmetry Partners LLC

Symmetry Partners LLC bought a new position in DexCom, Inc. (NASDAQ:DXCMFree Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,454 shares of the medical device company’s stock, valued at approximately $202,000.

A number of other hedge funds also recently bought and sold shares of DXCM. Prudential PLC lifted its position in DexCom by 49.2% in the 3rd quarter. Prudential PLC now owns 20,562 shares of the medical device company’s stock worth $1,918,000 after buying an additional 6,777 shares during the last quarter. QRG Capital Management Inc. purchased a new position in DexCom in the 3rd quarter worth approximately $866,000. Envestnet Portfolio Solutions Inc. purchased a new position in DexCom in the 3rd quarter worth approximately $2,335,000. Envestnet Asset Management Inc. increased its stake in DexCom by 12.5% in the 3rd quarter. Envestnet Asset Management Inc. now owns 657,234 shares of the medical device company’s stock worth $61,320,000 after purchasing an additional 72,850 shares during the period. Finally, Nordea Investment Management AB increased its stake in DexCom by 78.0% in the 3rd quarter. Nordea Investment Management AB now owns 140,930 shares of the medical device company’s stock worth $13,431,000 after purchasing an additional 61,744 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 0.1 %

DexCom stock traded up $0.11 during mid-day trading on Tuesday, hitting $116.64. The company had a trading volume of 2,190,437 shares, compared to its average volume of 2,896,621. The company has a market capitalization of $46.39 billion, a PE ratio of 75.55, a price-to-earnings-growth ratio of 2.83 and a beta of 1.22. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The stock’s 50 day moving average price is $127.10 and its two-hundred day moving average price is $125.99.

DexCom (NASDAQ:DXCMGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on DXCM shares. Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Canaccord Genuity Group boosted their target price on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. UBS Group boosted their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Redburn Atlantic assumed coverage on DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Finally, Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $140.94.

View Our Latest Stock Analysis on DexCom

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other DexCom news, EVP Sadie Stern sold 4,137 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $140.00, for a total value of $579,180.00. Following the completion of the sale, the executive vice president now owns 76,304 shares in the company, valued at $10,682,560. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,837 shares of company stock valued at $8,377,125. 0.30% of the stock is owned by company insiders.

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.